Shareholder Trent Miracle to Lead National Pharmaceutical Litigation Group
The Simmons Hanly Conroy, a leading national law firm in the fight against mesothelioma and other asbestos-related diseases, has appointed shareholder Trent Miracle to lead the firm’s growing pharmaceutical practice, which already is recognized on the national stage for its groundbreaking litigation of drug and supplement cases against major pharmaceutical companies.
“When people have been injured by defective drugs or medical devices, Simmons Hanly Conroy has helped them stand up, speak out, and receive the compensation they deserve,” Chairman and CEO John Simmons said. “We’re confident that Trent Miracle, a very successful litigator and proven leader, will provide the vision and commitment to our clients that will make a real difference. He will direct a team of experienced attorneys capable of navigating the complicated world of pharmaceutical litigation.”
The Simmons Hanly Conroy has represented thousands of pharmaceutical clients and recovered nearly $200 million in verdicts and settlements. “Our success comes through our thorough understanding of our clients’ particular medical histories weighed against the manufacturers’ legal obligations for safe testing, warnings, and labels,” Miracle said.
In addition to Miracle’s work on behalf of the firm’s mesothelioma clients, he has worked extensively litigating against the development and marketing of dangerous drugs such as Vioxx, Bextra, Ortho Evra, Ephedra and Phenylpropanolamine (PPA), Oxycontin, and others. He is currently representing individuals suffering serious side effects from taking the heartburn and acid reflux medication Reglan.
“Reglan is a prescription drug used to treat a number of gastrointestinal conditions,” Miracle said. “The FDA approved Reglan for short-term treatment only after other methods failed. Treatment with Reglan should not exceed three months. However, evidence shows that one-third of patients are prescribed the drug for longer periods, which is against FDA recommendations. Reglan can cause serious side effects.”
“Just as we are committed to fighting for victims of mesothelioma and other asbestos-related diseases, we are taking a leadership role in standing up for individuals who have been injured by dangerous or defective drugs,” said Managing Shareholder Michael Angelides.
The Simmons Hanly Conroy, recognized nationally as a leader in the fight against mesothelioma, also has practice areas in pharmaceutical litigation, intellectual property, and business litigation.
